Research progress of interleukin-15 in cancer immunotherapy

10Citations
Citations of this article
35Readers
Mendeley users who have this article in their library.

Abstract

Interleukin-15 (IL-15) is a cytokine that belongs to the interleukin-2 (IL-2) family and is essential for the development, proliferation, and activation of immune cells, including natural killer (NK) cells, T cells and B cells. Recent studies have revealed that interleukin-15 also plays a critical role in cancer immunotherapy. Interleukin-15 agonist molecules have shown that interleukin-15 agonists are effective in inhibiting tumor growth and preventing metastasis, and some are undergoing clinical trials. In this review, we will summarize the recent progress in interleukin-15 research over the past 5 years, highlighting its potential applications in cancer immunotherapy and the progress of interleukin-15 agonist development.

Cite

CITATION STYLE

APA

Cai, M., Huang, X., Huang, X., Ju, D., Zhu, Y. Z., & Ye, L. (2023). Research progress of interleukin-15 in cancer immunotherapy. Frontiers in Pharmacology. Frontiers Media S.A. https://doi.org/10.3389/fphar.2023.1184703

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free